New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge,…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the…
February 06, 2026 17:17 ET | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon…
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not…
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not…
February 06, 2026 19:00 ET | Source: Cannabix Technologies Inc. NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR…
New York, NY, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not…
February 06, 2026 03:30 ET | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06,…
VALNEVA Declaration of shares and voting rights January 31, 2026__________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât.…
2025/26Interim financial results, Q1 2025/261 October 2025 - 31 December 2025 Coloplast delivered Q1 organic growth of 6% and EBIT…